

Table 6: Supplements – Subcohorts of controls and their CSF test results

	Intrathecal CXCL13 (pg/ml)	CSF cell count (threshold <5/μl)	Borrelia antibody index (threshold <1.6)	CSF-protein (threshold <46mg/dl)
	Mean (SD), min, max	Mean (SD), min, max	Mean (SD), min, max	Mean (SD), min, max
Meningitis/Encephalitis				
Viral meningitis (n=18)	71 (124), min: 0, max: 530	243 (206), min: 11, max: 609	0.1 (0.2), min: 0, max: 0.9	76 (38), min: 33, max: 182
Bacterial meningitis (n=3)	17 (15), min: 0, max: 27	10939 (18124), min: 14, max: 31861	0.5 (0.7), min: 0, max: 0.9	247 (307), min: 47, max: 600
Autoimmune meningitis (n=3)	260 (427), min: 0, max: 753	16 (22), min: 3, max: 41	0.4 (0.6), min: 0, max: 0.8	40 (29), min: 19, max: 73
Neurosarcoidosis (n=1)	1272	167	0	133
Chronic meningitis (n=1)	49	23	0	66
Peripheral nerve disorders, other than AIDP/CIDP				
Motor neuron diseases (n=5)	4 (5), min: 0, max: 10	2 (1), min: 1, max: 3	0.2 (0.4), min: 0, max: 1	43 (14), min: 30, max: 60
Neuralgic amyotrophy (n=3)	0 (0), min: 0, max: 0	4 (4), min: 1, max: 8	0 (0), min: 0, max: 0	35 (2), min: 33, max: 37
Plexus neuritis, other than neuralgic amyotrophy (n=3)	136 (228), min: 0, max: 400	38 (64), min: 0, max: 111	0 (0), min: 0, max: 0	86 (47), min: 53, max: 140
Radiculitis (n=3)	56 (56), min: 0, max: 111	75 (82), min: 2, max: 163	0 (0), min: 0, max: 0	51 (17), min: 38, max: 70
Non-inflammatory radiculopathy (n=3)	60 (103), min: 0, max: 179	3 (2), min: 1, max: 4	0.5 (0.7), min: 0, max: 1	76 (56), min: 37, max: 140
Non-inflammatory mononeuropathy (n=6)	2 (4), min: 0, max: 10	4 (4), min: 1, max: 11	0 (0), min: 0, max: 0	52 (18), min: 25, max: 74
Non-inflammatory polyneuropathy (n=4)	3 (4), min: 0, max: 9	3 (2), min: 1, max: 6	0 (0), min: 0, max: 0	54 (24), min: 28, max: 86
Other cranial nerve disorders				
Infectious diseases (n=6)	24 (28), min: 0, max: 65	50 (86), min: 1, max: 222	0.6 (0.9), min: 0, max: 2	54 (16), min: 41, max: 80
Diabetogenic (n=1)	0	1	n.d.	57
Traumatic (n=1)	0	6	0	63
Trigeminal neuralgia (n=1)	0	2	0.8	73
Idiopathic (n=14)	28 (106), min: 0, max: 396	4 (4), min: 1, max: 12	0.2 (0.5), min: 0, max: 1.2	55 (25), min: 15, max: 101
Headache, other than meningitis				
Migraine (n=15)	2 (3), min: 0, max: 9	2 (2), min: 0, max: 6	0 (0), min: 0, max: 0	40 (12), min: 17, max: 63
Tension type headache (n=11)	2 (4), min: 0, max: 13	3 (2), min: 1, max: 6	0 (0), min: 0, max: 0	47 (26), min: 22, max: 122
Acute infection, accompanied by headache (n=13)	1 (5), min: 0, max: 17	4 (6), min: 1, max: 19	0 (0), min: 0, max: 0	39 (20), min: 16, max: 91
Normal pressure hydrocephalus (n=7)	3 (3), min: 0, max: 8	1.1 (0.4), min: 1, max: 2	0 (0), min: 0, max: 0	59 (26), min: 32, max: 111
Idiopathic intracranial headache (n=5)	1 (2), min: 0, max: 5	3 (2), min: 1, max: 5	0 (0), min: 0, max: 0	33 (16), min: 12, max: 50
Vasculitic headache (n=1)	5	2	n.d.	22
Other headaches (n=9)	7 (13), min: 0, max: 40	12 (26), min: 1, max: 81	0 (0), min: 0, max: 0	46 (12), min: 30, max: 67
Other, including epilepsy				
Movement disorders (n=7)	2 (4), min: 0, max: 11	4 (5), min: 0, max: 14	0.2 (0.5), min: 0, max: 1.2	57 (55), min: 20, max: 178
Psychiatric disorders (n=7)	0.1 (0.4), min: 0, max: 1	8 (14), min: 1, max: 40	0.3 (0.6), min: 0, max: 1.2	43 (18), min: 21, max: 72
Transverse myelitis (n=6)	30 (46), min: 0, max: 111	7 (7), min: 1, max: 18	0.3 (0.4), min: 0, max: 0.9	40 (7), min: 30, max: 46
Epilepsy (n=5)	1 (2), min: 0, max: 5	5 (5), min: 0, max: 12	0 (0), min: 0, max: 0	43 (20), min: 23, max: 66
Brain tumour (n=3)	3 (6), min: 0, max: 10	6 (7), min: 1, max: 14	0 (0), min: 0, max: 0	37 (6), min: 33, max: 44
Myasthenia gravis (n=2)	0 (0), min: 0, max: 0	1 (0), min: 1, max: 1	0 (0), min: 0, max: 0	33 (4), min: 30, max: 36
Polymyositis (n=1)	0	0	0	32
PRES (n=1)	0	1	n.d.	156
Progressive multifocal leukoencephalopathy (PML) (n=1)	27	1	0	34
Steroid responsive encephalopathy (SREAT) (n=1)	5	10	n.d.	65
Brain lesions of unclear aetiology (n=14)	3 (4), min: 0, max: 10	4 (3), min: 0, max: 9	0 (0), min: 0, max: 0	37 (19), min: 18, max: 75
Other (n=37)	5 (19), min: 0, max: 112	2 (1), min: 0, max: 5	4 (20), min: 0, max: 107	40 (20), min: 15, max: 124

Table 1 Supplements: Subcohorts of controls and their CSF test results